SCHEMBL1649654

SCHEMBL1649654

NCCCN1c2ccccc2Sc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.89
KDM1A O60341 10/20 0.62
SIGMAR1 Q99720 2/20 0.62
HTR2A P28223 2/20 0.62
SLC22A1 O15245 1/20 0.62
PRNP P04156 1/20 0.62
TP53 P04637 1/20 0.62
CYP1A2 P05177 1/20 0.62
ADRB2 P07550 1/20 0.62
CHRM2 P08172 1/20 0.62
CHRM4 P08173 1/20 0.62
HTR1A P08908 1/20 0.62
CHRM5 P08912 1/20 0.62
ADRA2A P08913 1/20 0.62
CYP2D6 P10635 1/20 0.62
CHRM1 P11229 1/20 0.62
DRD2 P14416 1/20 0.62
TSHR P16473 1/20 0.62
ADRA2B P18089 1/20 0.62
ADRA2C P18825 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2921645 0.88 PIM1 (0.76) PIM1KDM1ASIGMAR1HTR2ASLC22A1
Iodide SCHEMBL31634400 0.86 PIM1 (0.73) PIM1KDM1ASIGMAR1HTR2ASLC22A1
Hydrochloric Acid SCHEMBL14697550 0.86 PIM1 (0.73) PIM1KDM1ASIGMAR1HTR2ASLC22A1
Iodide SCHEMBL31634399 0.86 PIM1 (0.73) PIM1KDM1ASIGMAR1HTR2ASLC22A1
SCHEMBL11346620 0.86 PIM1 (0.68) PIM1KDM1ASIGMAR1HTR2ASLC22A1
SCHEMBL21196596 0.86 PIM1 (0.68) PIM1KDM1ASIGMAR1HTR2ASLC22A1
Nor2-Chlorpromazine SCHEMBL11202527 0.86 LMNA (0.70) PIM1KDM1ASIGMAR1HTR2ASLC22A1
SCHEMBL208025 0.86 PIM1 (0.79) PIM1KDM1ASIGMAR1HTR2ASLC22A1
Nor2-Chlorpromazine SCHEMBL14697764 0.85 LMNA (0.70) PIM1KDM1ASIGMAR1HTR2ASLC22A1
SCHEMBL10374624 0.83 PIM1 (0.63) PIM1KDM1ASIGMAR1HTR2ASLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675814-A1 COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES Bläss, Markus (DE) 2020-07-08 EP claimed
WO-2019043064-A1 COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES BLAESS MARKUS (DE) 2019-03-07 WO claimed
US-5744429-A FLOW CONTROL AGENTS EXXON CHEMICAL PATENTS INC (US) 1998-04-28 US claimed
EP-0375503-B1 Additives to lubricants resulting from the condensation of an alkylene polyamine onto a copolymer having contiguous carboxylic groups ELF AQUITAINE (FR) 1996-02-28 EP claimed
US-5055213-A Addition copolymers containing maleic anhydride monomer modifi ed by a phenothiazine derivative, napthtylamine or diphenylami ne; antideposit agents; dispersants; oxidation resistance SOCIETE NATIONALE ELF AQUITAINE (FR) 1991-10-08 US claimed
EP-3675814-A1 COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES Bläss, Markus (DE) 2020-07-08 EP disclosed
WO-2019043064-A1 COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES BLAESS MARKUS (DE) 2019-03-07 WO disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
WO-2014093225-A2 POLYCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME CELLCEUTIX CORPORATION (US) 2014-06-19 WO disclosed
WO-2014086478-A1 INHIBITORS OF MALT1 PROTEASE Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2014-06-12 WO disclosed
WO-2014086478-A1 INHIBITORS OF MALT1 PROTEASE Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2014-06-12 WO disclosed
US-5055213-A Addition copolymers containing maleic anhydride monomer modifi ed by a phenothiazine derivative, napthtylamine or diphenylami ne; antideposit agents; dispersants; oxidation resistance SOCIETE NATIONALE ELF AQUITAINE (FR) 1991-10-08 US disclosed
EP-0377358-A2 Nitrogen-bearing additives having antioxidant properties, and lubricant compositions comprising same ELF ANTAR FRANCE (FR) 1990-07-11 EP disclosed
EP-0375503-A1 Additives to lubricants resulting from the condensation of an alkylene polyamine onto a copolymer having contiguous carboxylic groups ELF AQUITAINE (FR) 1990-06-27 EP disclosed
EP-0200450-B1 TRICYCLIC DERIVATIVESOF THIADIAZOLE OXIDES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-01-03 EP disclosed
US-4719174-A USING ABSORPTIVE COMPOUND WHICH RELEASES ELECTRONS UPON EXPOSURE FUJI PHOTO FILM CO., LTD. (JP) 1988-01-12 US disclosed
US-4668671-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1987-05-26 US disclosed
EP-0200450-A2 Tricyclic derivativesof thiadiazole oxides SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1986-11-05 EP disclosed
US-4607006-A Silver halide photographic light-sensitive material containing non-spectral sensitizing electron donative silver halide adsorptive compound FUJI PHOTO FILM CO., LTD. (JP) 1986-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same ALG1, CD44, MUC1 PIM1 1725/4885KDM1A 3839/4885SIGMAR1 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.